GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » XSpray Pharma AB (OSTO:XSPRAY) » Definitions » Capex-to-Operating-Income

XSpray Pharma AB (OSTO:XSPRAY) Capex-to-Operating-Income : 0.00 (As of Mar. 2025)


View and export this data going back to 2017. Start your Free Trial

What is XSpray Pharma AB Capex-to-Operating-Income?

Capex-to-Operating-Income measures a company's investments in physical assets such as property, industrial buildings or equipment to its operating income.

XSpray Pharma AB's Capital Expenditure for the three months ended in Mar. 2025 was kr-14.70 Mil. Its Operating Income for the three months ended in Mar. 2025 was kr-39.47 Mil.

GuruFocus do not calculate Capex-to-Operating-Income if the Operating Income is negative.


XSpray Pharma AB Capex-to-Operating-Income Historical Data

The historical data trend for XSpray Pharma AB's Capex-to-Operating-Income can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

XSpray Pharma AB Capex-to-Operating-Income Chart

XSpray Pharma AB Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Capex-to-Operating-Income
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

XSpray Pharma AB Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Capex-to-Operating-Income Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of XSpray Pharma AB's Capex-to-Operating-Income

For the Biotechnology subindustry, XSpray Pharma AB's Capex-to-Operating-Income, along with its competitors' market caps and Capex-to-Operating-Income data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


XSpray Pharma AB's Capex-to-Operating-Income Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, XSpray Pharma AB's Capex-to-Operating-Income distribution charts can be found below:

* The bar in red indicates where XSpray Pharma AB's Capex-to-Operating-Income falls into.


;
;

XSpray Pharma AB Capex-to-Operating-Income Calculation

XSpray Pharma AB's Capex-to-Operating-Income for the fiscal year that ended in Dec. 2024 is calculated as

Capex-to-Operating-Income=- Capital Expenditure / Operating Income
=- (-42.142) / -283.236
=N/A

XSpray Pharma AB's Capex-to-Operating-Income for the quarter that ended in Mar. 2025 is calculated as

Capex-to-Operating-Income=- Capital Expenditure / Operating Income
=- (-14.701) / -39.465
=N/A

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


XSpray Pharma AB  (OSTO:XSPRAY) Capex-to-Operating-Income Explanation

Capex-to-Operating-Income assesses how much emphasis a company is placing upon investing in capital-intensive projects. The ratio is generally a good gauge to quantify how much focus on growth a company has. Typically, smaller companies that are still growing and expanding will have a higher Capex to Operating Income Ratio, since such businesses are likely investing more in physical assets. Lower ratios could indicate that a company has reached maturity and it is no longer pursuing aggressive growth.


XSpray Pharma AB Capex-to-Operating-Income Related Terms

Thank you for viewing the detailed overview of XSpray Pharma AB's Capex-to-Operating-Income provided by GuruFocus.com. Please click on the following links to see related term pages.


XSpray Pharma AB Business Description

Traded in Other Exchanges
Address
Scheeles vag 2, Solna, SWE, SE-171 65
XSpray Pharma AB is a pharmaceutical company focused on developing improved PKIs for cancer treatment, leveraging its proprietary HyNap technology platform. The company aims to enhance clinical outcomes for cancer patients by improving the efficacy, safety, and patient experience of existing cancer therapies. Its product portfolio includes Dasynoc and other product candidates in different stages of development such as XS003 nilotinib, XS008 axitinib, and other.

XSpray Pharma AB Headlines

No Headlines